Preclinical antitumor activity of the oral platinum analog satraplatin

Cancer Chemotherapy and Pharmacology

Volumn 60, Issue 4, 2007, Pages 589-600

  Wosikowski, Katja ^a   Lamphere, Lou ^b   Unteregger, Gerhard ^c   Jung, Volker ^c   Kaplan, Faith ^b   Xu, Jimmy P ^b   Rattel, Benno ^a   Caligiuri, Maureen ^b  

^a GPC Biotech   (Germany)

^b GPC Biotech   (United States)

^c SAARLAND UNIVERSITY   (Germany)

Author keywords

Drug resistance; JM 118; Platinum; Prostate cancer; Satraplatin

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CAMPTOTHECIN; CISPLATIN; DNA TOPOISOMERASE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FINASTERIDE; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; NSC 266046; OXALIPLATIN; PACLITAXEL; PLATINUM AMMINE CYCLOHEXYLAMINE DICHLORIDE; PLATINUM DERIVATIVE; PROSTATE SPECIFIC ANTIGEN; SATRAPLATIN; TUBULIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER MODEL; CANCER RESISTANCE; CELL COUNT; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; LEUKEMIA; LUNG CANCER; MALE; MOUSE; NONHUMAN; NUDE MOUSE; OVARY CARCINOMA; PRIORITY JOURNAL; PROSTATE CANCER; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE; TUMOR XENOGRAFT;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MICE; MICE, NUDE; ORGANOPLATINUM COMPOUNDS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34447536763     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0502-z     Document Type: Article

References (46)

1. Hartmann JT, Lipp HP (2003) Toxicity of platinum compounds. Expert Opin Pharmacother 4:889-901
2. Petrylak DP, Sartor O, Witjes F, Ferrero J, Berry WR, Koletsky A, Falcon S, Nathan FE, Petrone ME, Sternberg C (2007) A phase III, randomized, double-blind trial of satraplatin and prednisone vs placebo and prednisone for patients with hormone refractory prostate cancer. ASCO Prostate Cancer Proceedings: Abstract 145
3. Mellish KJ, Barnard CF, Murrer BA, Keller LR (1995) DNA-binding properties of novel cis- and trans platinum-based anticancer agents in 2 human ovarian carcinoma cell lines. Int J Cancer 62:717-723
4. Fink D, Nebel S, Aebi S, Zheng H, Cenni B, Nehme A, Christen RD, Howell SB (1996) The role of DNA mismatch repair in platinum drug resistance. Cancer Res 56:4881-4886
5. Kelland LR, Abel G, McKeage MJ, Jones M, Goddard PM, Valenti M, Murrer BA, Harrap KR (1993) Preclinical antitumor evaluation of bis-acetato-ammine- dichloro-cyclohexylamine platinum (IV): an orally active platinum drug. Cancer Res 53:2581-2586
6. Mellish KJ, Kelland LR, Harrap KR (1993) In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin. Br J Cancer 68:240-250
7. Twentyman PR, Wright KA, Mistry P, Kelland LR, Murrer BA (1992) Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin. Cancer Res 52:5674-5680
8. O'Neill CF, Hunakova L, Kelland LR (1999) Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells. Chem Biol Interact 123:11-29
9. Dixon SC, Knopf KB, Figg WD (2001) The control of prostate-specific antigen expression and gene regulation by pharmacological agents. Pharmacol Rev 53:73-91
10. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer drug screening. J Natl Cancer Inst 82:1107-1112
11. Straub B, Müller M, Krause H, Schrader M, Goessl C, Heicappell R, Miller K (2001) Detection of prostate-specific antigen RNA before and after radical retropubic prostatectomy and transurethral resection of the prostate using "Light-cycler"-based quantitative real-time polymerase chain reaction. Urology 58:815-820
12. Straub B, Müller M, Krause H, Schrader M, Miller K (2003) Quantitative real-time RT-PCR for detection of circulating prostate-specific antigen mRNA using sequence-specific oligonucleotide hybridization probes in prostate cancer patients. Oncology 65(suppl 1):12-17
13. Grever MR, Schepartz SA, Chabner BA (1992) The National Cancer Institute: cancer drug discovery and development program. Semin Oncol 19:622-638
14. NCI/NIH Developmental Therapeutics Program human cell line screen Available at: http://www.dtp.nci.nih.gov
15. Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, Plowman J, Boyd MR (1989) Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 81:1088-1092
16. Grieshaber CK, Marsoni S (1986) Relation of preclinical toxicology to findings in early clinical trials. Cancer Treat Rep 70:65-72
17. Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K, Fojo T (1996) Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 52:1855-1865
18. Casazza AM, Fairchild CR (1996) Paclitaxel (Taxol): mechanisms of resistance. Cancer Treat Res 87:149-171
19. Cabral F, Abraham I, Gottesman MM (1981) Isolation of a taxol-resistant Chinese hamster ovary cell mutant that has an alteration in alpha-tubulin. Proc Natl Acad Sci USA 78:4388-4391
20. Schibler MJ, Cabral F (1986) Taxol-dependent mutants of Chinese hamster ovary cells with alterations in alpha- and beta-tubulin. J Cell Biol 102:1522-1531
21. Murphy LD, Herzog CE, Rudick JB, Fojo AT, Bates SE (1990) Use of the polymerase chain reaction in the quantitation of mdr-1 gene expression. Biochemistry 29:10351-10356
22. Minotti AM, Barlow SB, Cabral F (1991) Resistance to antimitotic drugs in Chinese hamster ovary cells correlates with changes in the level of polymerized tubulin. J Biol Chem 266:3987-3994
23. Haber M, Burkhart CA, Regl DL, Madafiglio J, Norris MD, Horwitz SB (1995) Altered expression of M beta 2, the class II beta-tubulin isotype, in a murine J774.2 cell line with a high level of taxol resistance. J Biol Chem 270:31269-31275
24. Ohta S, Nishio K, Kubota N, Ohmori T, Funayama Y, Ohira T, Nakajima H, Adachi M, Saijo N (1994) Characterization of a taxol-resistant human small-cell lung cancer cell line. Jpn J Cancer Res 85:290-297
25. Giannakakou P, Sackett DL, Kang YK, Zhan Z, Buters JT, Fojo T, Poruchynsky MS (1997) Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 272:17118-17125
26. Pizzolato JF, Saltz LB (2003) The camptothecins. Lancet 361:2235-2242
27. Liu LF, Desai SD, Li TK, Mao Y, Sun M, Sim SP (2000) Mechanism of action of camptothecin. Ann N Y Acad Sci 922:1-10
28. Kapoor R, Slade DL, Fujimori A, Pommier Y, Harker WG (1995) Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin. Oncol Res 7:83-95
29. Glavinas H, Krajcsi P, Cserepes J, Sarkadi B (2004) The role of ABC transporters in drug resistance, metabolism and toxicity. Curr Drug Deliv 1:27-42
30. Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2:48-58
31. Perego P, De Cesare M, De Isabella P, Carenini N, Beggiolin G, Pezzoni G, Palumbo M, Tartaglia L, Pratesi G, Pisano C, Carminati P, Scheffer GL, Zunino F (2001) A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line. Cancer Res 61:6034-6037
32. Hector S, Bolanowska-Higdon W, Zdanowicz J, Hitt S, Pendyala L (2001) In vitro studies on the mechanisms of oxaliplatin resistance. Cancer Chemother Pharmacol 48:398-406
33. Schneider E, Horton JK, Yang CH, Nakagawa M, Cowan KH (1994) Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Res 54:152-158
34. Alvarez M, Paull K, Monks A, Hose C, Lee JS, Weinstein J, Grever M, Bates S, Fojo T (1995) Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen. J Clin Invest 95:2205-2214
35. Sternberg CN, Whelan P, Hetherington J, Paluchowska B, Slee PH, Vekemans K, Van Erps P, Theodore C, Koriakine O, Oliver T, Lebwohl D, Debois M, Zurlo A, Collette L, Genitourinary Tract Group of the EORTC (2005) Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology 68:2-9
36. Fokkema E, Groen HJ, Bauer J, Uges DR, Weil C, Smith IE (1999) Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell lung cancer. J Clin Oncol 17:3822-3827
37. Sova P, Mistr A, Kroutil A, Zak F, Pouckova P, Zadinova M (2006) Comparative anti-tumor efficacy of two orally administered platinum (IV) drugs in nude mice bearing human tumor xenografts. Anticancer Drugs 17:201-206
38. Raynaud FI, Boxall FE, Goddard P, Barnard CF, Murrer BA, Kelland LR (1996) Metabolism, protein binding and in vivo activity of the oral platinum drug JM216 and its biotransformation products. Anticancer Res 16:1857-1862
39. Loh SY, Mistry P, Kelland LR, Abel G, Harrap KR (1992) Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes. Br J Cancer 66:1109-1115
40. Kelland LR, Murrer BA, Abel G, Giandomenico CM, Mistry P, Harrap KR (1992) Ammine/amine platinum (IV) dicarboxylates: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res 52:822-828
41. Samimi G, Howell SB (2006) Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters. Cancer Chemother Pharmacol 57: 781-788
42. Fokkema E, Groen HJ, Helder MN, de Vries EG, Meijer C (2002) JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin. Biochem Pharmacol 63:1989-1996
43. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA, TAX 327 Investigators (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512
44. Dagher R, Li N, Abraham S, Rahman A, Sridhara R, Pazdur R (2004) Approval summary: Docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer. Clin Cancer Res 10:8147-8151
45. Amorino GP, Mohr PJ, Hercules SK, Pyo H, Choy H (2000) Combined effects of the orally active cisplatin analog, JM216, and radiation in antitumor therapy. Cancer Chemother Pharmacol 46:423-426
46. Cmelak A, Choy H, Murphy B, DeVore R, Bria B, Day T, Porte K, Johnson D (1999) Phase I study of JM-216 with concurrent radiation in non-small cell lung cancer and squamous cell head and neck cancer. Proc Am Soc Clin Oncol 18 (abstract 1520)